Task: Answer Verification
Input (English): Question: Does the use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer affect progression-free or overall survival?
Answer: The current results indicated that there was no difference in cancer-related PFS or OS with use of ESA in this cohort of women treated for ovarian cancer.
Output (English): no